Merck grows Keytruda indications with head and neck cancer approval
Merck’s checkpoint star is shining a little brighter today with two new approvals in head and neck squamous cell carcinoma.
The pharma giant first clinched …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
